Fractyl Health is deprioritizing a type 2 diabetes trial in favor of a pivotal study of its endoscopy treatment Revita and ...

After the Phase II failure of its lead asset from Cerevel, AbbVie is resetting expectations and narrowing the clinical ...

While the former Biden administration showcased the Inflation Reduction Act as a key victory in the fight over high drug ...

Biogen’s effort to buy Sage against the board’s wishes and a long-time effort by investor Alcorn to scuttle Aurion’s IPO ...

The greenlight for Journavx (suzetrigine), which comes on the heels of a $7.4 billion opioid settlement, could spark momentum ...

Blackstone joins other big investors such as ARCH Venture Partners and Bain Capital Life Sciences in pumping billions of ...

Novartis was among the most prolific pharma dealmakers in 2024, a trend that it expects to continue with more bolt-on deals this year to set up for sustainable long-term growth.

ImmunityBio will part with 10 employees this quarter. Last fall, it cut 31 employees. The moves come as the biotech works to advance Anktiva in non-small cell lung cancer.

The approval of Axsome Therapeutics’ Symbravo for migraine with or without aura came alongside the greenlight for Vertex's non-opioid treatment Journavx.

Little information has emerged about osavampator, a potentially first-in-class drug, since its promising Phase II performance last spring.

Senators on the Health, Education, Labor, and Pensions committee were critical of Kennedy’s long history as an anti-vaccine campaigner.

Analysts were unfazed by the news that Takeda will cease development of soticlestat after Phase III failures, while ...